Our researchers designed an immunogenic viral peptide-linked NRP1 antibody to redirect circulating T cells.

This strategy engaged pre-existing antiviral T cells to eliminate tumors, highlighting a potential therapeutic platform against NRP1-expressing cancers. #AACR26